Dr. Yardley on HERMIONE-2 Trial for HER2+ Breast Cancer

Video

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the phase II HERMIONE-2 trial, which is a randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in patients with anthracycline-naive HER2-positive, locally advanced/metastatic breast cancer who were previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the phase II HERMIONE-2 trial, which is a randomized, open-label trial comparing MM-302 plus trastuzumab (Herceptin) with chemotherapy plus trastuzumab in patients with anthracycline-naïve, locally advanced, HER2-positive breast cancer who were previously treated with pertuzumab (Perjeta) and ado-trastuzumab emtansine (T-DM1).

This ongoing trial is addressing an unmet need, as there is a rising incidence of HER2-positive patients who are anthracycline-naive, Yardley explains. In the study, patients in the MM-302 arm receive the novel antibody-drug conjugate once every 3 weeks.

The primary endpoint of the study, she adds, is progression-free survival. The safety of MM-302 in combination with trastuzumab will also be explored.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD